Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD5305 + AZD5335 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5305 | AZD 5305|AZD-5305 | PARP-1 Inhibitor 8 | AZD5305 inhibits PARP1, potentially inhibiting cell growth and inducing tumor regression (PMID: 35929986). | |
AZD5335 | AZD 5335|AZD-5335 | FOLR1-targeted Therapy 19 | AZD5335 is an antibody-drug conjugate (ADC) comprising an antibody targeting FOLR1 (FRalpha) linked to a topoisomerase 1 inhibitor, which potentially inhibits tumor growth (Cancer Res (2023) 83 (8_Supplement): LB025). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05797168 | Phase Ib/II | AZD5305 + AZD5335 AZD5335 | Phase I/IIa Study for AZD5335 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors (FONTANA) | Recruiting | USA | GBR | ESP | CAN | AUS | 4 |